Eledon Pharmaceuticals Inc. (ELDN)
NASDAQ: ELDNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELDN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $150.34M
- EPS (TTM)
- -$0.73
- Dividend yield
- None
- 52-week range
- 1.39 – 4.49
- Day range
- 1.76 – 2.00
- Volume / Avg
- 1.29M / 931.77K
- Beta
- —
- Shares outstanding
- 84.46M
52-week range
ELDN stock today
On Nov 20, ELDN ended the session at $1.78, shedding $0.12 (6.32%), versus the S&P 500's 3.70% decline. Shares are 60.4% below their 52-week high of $4.49, set on Jun 22, 2026 and 28.5% above the 52-week low of $1.39, near the bottom of the past year's range. ELDN is up 17.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 23.6%.
Eledon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.73), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Eledon Pharmaceuticals
Company profileEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. David-Alexandre C. Gros M.D., Ph.D.
- Headquarters
- Irvine, CA
- Employees
- 33
- IPO year
- 2014
- Website
- eledon.com
Financial highlights
Full financialsEledon Pharmaceuticals reported a net loss of $45.6 million, compared with a loss of $36.2 million a year earlier. Diluted earnings per share came in at -$0.52.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-45.62M | $-36.18M | $-116.54M | $-87.97M | $-34.51M |
| EPS (diluted) | $-0.52 | $-0.66 | $-4.73 | $-6.16 | $-2.33 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$9.00+405.62%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.03 vs $-0.20
- Surprise
- +85.00%
ELDN news
All ELDN newsEledon Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RNAAtrium Therapeutics Inc. | 6.92 | -0.86% | $149.27M | vs ELDN |
| IFRXInflaRx N.V. | 1.04 | -4.59% | $153.26M | vs ELDN |
| VRXAVeraxa Biotech AG | 1.04 | +0.97% | $147.06M | vs ELDN |
| PRQRProQR Therapeutics N.V. | 1.04 | -0.95% | $146.98M | vs ELDN |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs ELDN |
| BBOTBridgeBio Oncology Therapeutics Inc. | 1.81 | -2.69% | $145.25M | vs ELDN |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs ELDN |
| ALXOALX Oncology Holdings Inc. | 1.06 | +3.92% | $137.03M | vs ELDN |
Indexes, lists and sector
Eledon Pharmaceuticals stock FAQ
What is Eledon Pharmaceuticals's stock price today?
ELDN last traded at $1.78 as of Nov 20, 4:00 PM EST, down 6.32% on the day. Prices are delayed at least 15 minutes.
Does Eledon Pharmaceuticals pay a dividend?
No. Eledon Pharmaceuticals does not currently pay a regular cash dividend.
Who is Eledon Pharmaceuticals's CEO?
Dr. David-Alexandre C. Gros M.D., Ph.D. is the chief executive officer of Eledon Pharmaceuticals Inc., which has about 33 employees.
Has ELDN ever split its stock?
Yes. The most recent ELDN stock split was a 1-for-18 split on Oct 5, 2020, one of 2 splits on record.
What is the ELDN 52-week high?
The 52-week high for ELDN is $4.49 and the 52-week low is $1.39. The stock is currently 60.4% below its high.